Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Inclusion Criteria: * Previously diagnosed with MM based on standard IMWG criteria and currently requires treatment. * Provided voluntary written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care * Age ≤ 75 years, with patients over the age of 70 requiring PI approval * Measurable disease defined as at least one of the following: * Serum M protein ≥ 0.5 g/dL (≥5 g/L) * Urine M protein ≥ 200 mg/24 hours * Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65) * Screening Laboratory evaluations within the following parameters * Absolute neutrophil count (ANC) ≥ 1,000 cells/dL (1.0 x 109/L) (Growth factors cannot be used within 14 days before first drug administration) * Platelet count ≥ 75,000 cells/dL (75 x 109/L) if \< 50% BM nucleated cells are plasma cells, ≥ 30,000 cells/dL if ≥ 50% of BM nucleated cells are plasma cells. (without transfusions required during the 3 days prior to the screening hematologic test) * Total Bilirubin ≤ 2.0 X upper limit of normal (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL) * AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN * Calculated creatinine clearance ≥ 30 mL/min * Hemoglobin ≤ 8 g/dL * ECOG performance status ≤ 2 (Appendix A) * Participant…